GL1X · GenesisL1 explorer

MolNFT v1 · #160044 · protein

Crystal structure of human KRAS G12C covalently bound to an acryloylazetidine acetamide inhibitor.

6P8Y · GTPase KRAS: “Crystal structure of human KRAS G12C covalently bound to an acryloylazetidine acetamide inhibitor.”. X-ray diffraction, 3 ligands (GDP, O5Y, MG), 3 pockets (best druggability 0.61). MolNFT v1 #160044 on GenesisL1: 3D…

PDB
6P8Y
Type
protein
Length
324 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
GTPase KRAS
UniProt
P01116
Ligands
GDP, O5Y, MG
Pockets
3 · best druggability 0.61

Structure

x-ray diffraction · 2 distinct chains · 35% helix, 26% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AGTPase KRASprotein16636% helix, 25% strandP01116
BGTPase KRASprotein15834% helix, 27% strandP01116

Ligands and binding sites

  • GDP · Guanosine-5'-diphosphate · ligand · 2 copies · chains A, B
  • O5Y · 2-[5-bromo-3-(5-methoxy-3,4-dihydroisoquinoline-2(1H)-carbonyl)-1H-indol-1-yl]-N-(1-propanoylazetidin-3-yl) acetamide · ligand · 2 copies · chains A, B
  • MG · Magnesium ion · metal · 2 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

3 pockets found on a 1 Å grid, 2 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
14250.610.7642empty
22170.560.7839MG, GDP, O5Y
31140.400.7626MG, GDP

Interfaces

1 interface between chains.

  • A–B · 404 Ų buried · 6 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 2 covalent (covalent ligand).

Compared structures

  • 6P8Y · Crystal structure of human KRAS G12C covalently bound to an acryloylazetidine acetamide… · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.